U.S. Industrial REITs Stock News

ETHZilla Corporation recently completed a 1-for-10 stock split on October 20, 2025, and appointed John D. Kristoff as Senior Vice President, Corporate Communications and Investor Relations, reporting directly to Chairman and CEO McAndrew Rudisill. This combination of a share structure change and the creation of a high-level communications and investor relations role highlights ETHZilla's focus on expanding accessibility and strengthening its engagement with both investors and the...

Earlier this week, Alector and its partner GSK announced that latozinemab failed to meet safety and efficacy criteria in a Phase 3 clinical trial for frontotemporal dementia due to GRN gene mutations, leading to the discontinuation of related studies and a workforce reduction of approximately 49%. This setback not only impacts Alector's core pipeline but also coincides with the resignation of its President and Head of R&D, highlighting significant changes in the company's direction. We'll...

Fortrea Holdings Inc. ( NASDAQ:FTRE ) insiders who purchased shares in the last 12 months were richly rewarded last...

Vimeo (VMEO) shares have quietly climbed in recent months, gaining over 90% in the past quarter. Investors seem to be taking a closer look at the company’s evolving business and recent annual growth figures. See our latest analysis for Vimeo. After a long stretch of mixed sentiment, Vimeo’s recent share price return of over 90% in the past quarter reflects renewed optimism and upward momentum. This is especially notable considering its 65% total shareholder return over the past year. While...

In recent days, Flux Power Holdings, Inc. filed a shelf registration statement to potentially offer up to US$19.57 million in common stock, comprising 3,644,289 shares. This move gives the company financial flexibility, potentially signaling preparations for future capital needs, business development plans, or expansion opportunities. We'll examine how the shelf registration could affect Flux Power Holdings' narrative, especially its impact on future funding and growth plans. Find companies...

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

We can readily understand why investors are attracted to unprofitable companies. For example, Telos ( NASDAQ:TLS...

Key Insights Institutions' substantial holdings in Voyager Therapeutics implies that they have significant influence...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Simpson Manufacturing Co., Inc. ( NYSE:SSD ), is not the largest company out there, but it saw a decent share price...

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

Coya Therapeutics, Inc. has completed a follow-on equity offering worth US$20,000,002, issuing 3,636,364 shares of common stock at US$5.50 per share. This capital raise signals the company’s focus on securing funding for continued development of its therapeutic programs and growth initiatives. With fresh capital in hand, we'll examine how the follow-on equity offering influences Coya Therapeutics' investment narrative and funding outlook. The end of cancer? These 27 emerging AI stocks are...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

If we're looking to avoid a business that is in decline, what are the trends that can warn us ahead of time? More often...

What are the early trends we should look for to identify a stock that could multiply in value over the long term? In a...

Major stock indexes in the United States recently ended lower as investors weighed earnings reports and ongoing U.S.-China trade tensions. In such a fluctuating market, penny stocks—despite their somewhat outdated moniker—remain a compelling area for investment, particularly when they are backed by solid financials. These smaller or newer companies can offer surprising value and potential for growth, making them worth considering for investors seeking hidden opportunities in quality stocks.

In October 2025, the U.S. stock market has been navigating a complex landscape marked by renewed U.S.-China trade tensions and mixed earnings reports, leading to declines in major indices such as the Nasdaq, Dow Jones Industrial Average, and S&P 500. Amidst this backdrop of uncertainty and fluctuating investor sentiment, identifying promising small-cap stocks can offer unique opportunities for those looking to uncover potential growth avenues in less-explored corners of the market.

As the U.S. stock market grapples with earnings reports and renewed U.S.-China trade tensions, major indices like the Nasdaq, Dow Jones Industrial Average, and S&P 500 have ended lower. In such uncertain times, dividend stocks can offer a reliable income stream for investors seeking stability amidst market volatility.

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Earlier this week, Verastem Oncology announced promising preliminary data from the Phase 1/2a clinical trial of VS-7375, an oral KRAS G12D inhibitor, in patients with advanced KRAS G12D mutant solid tumors, along with the initiation of a combination cohort with cetuximab. These findings are significant, as there are currently no FDA-approved therapies specifically targeting KRAS G12D mutations in cancer, addressing a critical gap for patients with limited treatment options. We'll explore how...

Altisource Portfolio Solutions (ASPS) remains unprofitable but has managed to reduce its annual losses by 33.9% per year over the past five years. While the company’s net income has not turned positive and profit growth has not accelerated recently, its Price-To-Sales Ratio of 0.8x stands well below the peer average of 3.4x and the US Real Estate sector average of 2.6x. Investor attention is likely to center on operational progress and revenue momentum, even as shareholder dilution and...